Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Spyre Therapeutics Inc shares valued at $435,356 were sold by Turtle Cameron on Dec 01 ’25. At $29.02 per share, Turtle Cameron sold 15,000 shares. The insider’s holdings dropped to 686,907 shares worth approximately $23.02 million following the completion of this transaction.
Also, Turtle Cameron sold 45,000 shares, netting a total of over 1,049,778 in proceeds. Following the sale of shares at $23.33 each, the insider now holds 701,907 shares.
Before that, CAMERON TURTLE had added 90,000 shares to its account. In a trade valued at $2,201,400, the Director bought Spyre Therapeutics Inc shares for $24.46 each.
As published in their initiating research note from Deutsche Bank on September 26, 2025, Spyre Therapeutics Inc [SYRE] has been a Buy and the price target has been revised to $43. Analysts at Leerink Partners started covering the stock with ‘”an Outperform”‘ outlook in a report released in early April. As of March 18, 2025, Wolfe Research has initiated its “an Outperform” rating for SYRE. Earlier on September 04, 2024, Wedbush initiated its rating. Their recommendation was “an Outperform” for SYRE stock.
Analyzing SYRE Stock Performance
On last trading session, Spyre Therapeutics Inc [NASDAQ: SYRE] rose 4.07% to $33.51. The stock’s lowest price that day was $31.44, but it reached a high of $34.525 in the same session. During the last five days, there has been a surge of approximately 12.64%. Over the course of the year, Spyre Therapeutics Inc shares have jumped approximately 21.19%. Shares of the company reached a 52-week high of $34.54 on 12/04/25 and a 52-week low of $10.91 on 04/09/25.
Support And Resistance Levels for Spyre Therapeutics Inc (SYRE)
According to the 24-hour chart, there is a support level at 31.79, which, if violated, would cause prices to drop to 30.06. In the upper region, resistance lies at 34.89. The next price resistance is at 36.26. RSI (Relative Strength Index) is 77.80 on the 14-day chart, showing overbought technical sentiment.
Is Spyre Therapeutics Inc subject to short interest?
Stocks of Spyre Therapeutics Inc saw a sharp steep in short interest on 2025-11-14 dropping by -0.93 million shares to 12.46 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 13.39 million shares. A decline of -7.43% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 11.07 of the overall float, the days-to-cover ratio (short ratio) decline to 11.07.
Which companies own the most shares of Spyre Therapeutics Inc (SYRE)?
In terms of Spyre Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 43 in the next 12 months, up nearly 33.54% from the previous closing price of $32.2. Analysts anticipate Spyre Therapeutics Inc stock to reach 43 by 2025, with the lowest price target being 43. In spite of this, 3 analysts ranked Spyre Therapeutics Inc stock as Buy at the end of 2025.
